The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Zanubrutinib plus obinutuzumab receives positive CHMP opinion for the treatment of adult patients with R/R FL
On October 16, 2023, it was announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion for zanubrutinib, a Bruton’s tyrosine kinase inhibitor, plus obinutuzumab for the treatment of adult patients with relapsed/refractory follicular lymphoma who have received at least two prior lines of systemic therapy.1 This recommendation was based on positive data from the pivotal phase II ROSEWOOD trial (NCT03332017).1
ROSEWOOD is an ongoing global, phase II study investigating zanubrutinib plus obinutuzumab compared with obinutuzumab alone in 217 adult patients with relapsed/refractory follicular lymphoma who received at least two prior lines of systemic therapy. At a median follow-up of 20 months, the overall response rate was 69% versus 45.8% in the zanubrutinib plus obinutuzumab and obinutuzumab monotherapy arms, respectively (p = 0.0012); and treatment was well-tolerated.1
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
